Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen
Mammary carcinomas have been induced by 3.5 Gy whole-body gamma radiation administered at age 40 to 50 days to virgin female Sprague-Dawley rats. In 142 irradiated controls carcinoma incidence averaged 7.8% in survivors observed less than 300 days and 38.3% of those surviving longer (P less than 0.0...
Gespeichert in:
| Veröffentlicht in: | Cancer Jg. 63; H. 9; S. 1685 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.05.1989
|
| Schlagworte: | |
| ISSN: | 0008-543X |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Mammary carcinomas have been induced by 3.5 Gy whole-body gamma radiation administered at age 40 to 50 days to virgin female Sprague-Dawley rats. In 142 irradiated controls carcinoma incidence averaged 7.8% in survivors observed less than 300 days and 38.3% of those surviving longer (P less than 0.001 by t test). Mammary cancer promotion was inhibited by two methods: estriol (E3) 638 micrograms/month (2.2 microns/mo) subcutaneously for natural life span begun 2 weeks after exposure reduced cancer incidence from 76% in controls to 48% after 331 to 449 mean days observation until neoplasia was palpable (P less than 0.02 by chi-square analysis). Uterine weights were similar in control and treated groups, and were 15% to 18% greater than uteri of nonirradiated controls from other simultaneous experiments. Six monthly 638-micrograms doses of 17 alpha ethinyl estriol (EE3) reduced tumors from 88% in controls to 64% (P less than 0.05 by chi-square analysis) and delayed cancer onset (P less than 0.01-0.04 by life table analysis). Ethinyl estradiol (EE2) after 6 months' treatment similarly delayed mammary tumor development reducing incidence to 75% (NS), with a six-fold increase in nonmammary epithelial malignant tumors. Estriol administration begun between 3 days before to 5 days after radiation did not alter mammary cancer incidence in six experiments. Monthly implantation of 2.5 mg tamoxifen (4.44 microns/mo) started 2 weeks after radiation reduced mammary cancer incidence from 83% to 14% after 307 to 314 days' observation (P less than 0.001 by chi-square analysis). Treated rats had atrophic ovaries and uteri consistent with blockade of endogenous estradiol activity. Short-term parenteral E3 or EE3 therapy using 10 to 30 micrograms/kg/day (35-100 microns/kg/day) rapidly differentiated virgin rat mammary glands without impairment of subsequent estrus cycles and offers an alternative to castration or life-long antiestrogen therapy for reduction of risk of radiogenic mammary carcinoma. |
|---|---|
| AbstractList | Mammary carcinomas have been induced by 3.5 Gy whole-body gamma radiation administered at age 40 to 50 days to virgin female Sprague-Dawley rats. In 142 irradiated controls carcinoma incidence averaged 7.8% in survivors observed less than 300 days and 38.3% of those surviving longer (P less than 0.001 by t test). Mammary cancer promotion was inhibited by two methods: estriol (E3) 638 micrograms/month (2.2 microns/mo) subcutaneously for natural life span begun 2 weeks after exposure reduced cancer incidence from 76% in controls to 48% after 331 to 449 mean days observation until neoplasia was palpable (P less than 0.02 by chi-square analysis). Uterine weights were similar in control and treated groups, and were 15% to 18% greater than uteri of nonirradiated controls from other simultaneous experiments. Six monthly 638-micrograms doses of 17 alpha ethinyl estriol (EE3) reduced tumors from 88% in controls to 64% (P less than 0.05 by chi-square analysis) and delayed cancer onset (P less than 0.01-0.04 by life table analysis). Ethinyl estradiol (EE2) after 6 months' treatment similarly delayed mammary tumor development reducing incidence to 75% (NS), with a six-fold increase in nonmammary epithelial malignant tumors. Estriol administration begun between 3 days before to 5 days after radiation did not alter mammary cancer incidence in six experiments. Monthly implantation of 2.5 mg tamoxifen (4.44 microns/mo) started 2 weeks after radiation reduced mammary cancer incidence from 83% to 14% after 307 to 314 days' observation (P less than 0.001 by chi-square analysis). Treated rats had atrophic ovaries and uteri consistent with blockade of endogenous estradiol activity. Short-term parenteral E3 or EE3 therapy using 10 to 30 micrograms/kg/day (35-100 microns/kg/day) rapidly differentiated virgin rat mammary glands without impairment of subsequent estrus cycles and offers an alternative to castration or life-long antiestrogen therapy for reduction of risk of radiogenic mammary carcinoma. Mammary carcinomas have been induced by 3.5 Gy whole-body gamma radiation administered at age 40 to 50 days to virgin female Sprague-Dawley rats. In 142 irradiated controls carcinoma incidence averaged 7.8% in survivors observed less than 300 days and 38.3% of those surviving longer (P less than 0.001 by t test). Mammary cancer promotion was inhibited by two methods: estriol (E3) 638 micrograms/month (2.2 microns/mo) subcutaneously for natural life span begun 2 weeks after exposure reduced cancer incidence from 76% in controls to 48% after 331 to 449 mean days observation until neoplasia was palpable (P less than 0.02 by chi-square analysis). Uterine weights were similar in control and treated groups, and were 15% to 18% greater than uteri of nonirradiated controls from other simultaneous experiments. Six monthly 638-micrograms doses of 17 alpha ethinyl estriol (EE3) reduced tumors from 88% in controls to 64% (P less than 0.05 by chi-square analysis) and delayed cancer onset (P less than 0.01-0.04 by life table analysis). Ethinyl estradiol (EE2) after 6 months' treatment similarly delayed mammary tumor development reducing incidence to 75% (NS), with a six-fold increase in nonmammary epithelial malignant tumors. Estriol administration begun between 3 days before to 5 days after radiation did not alter mammary cancer incidence in six experiments. Monthly implantation of 2.5 mg tamoxifen (4.44 microns/mo) started 2 weeks after radiation reduced mammary cancer incidence from 83% to 14% after 307 to 314 days' observation (P less than 0.001 by chi-square analysis). Treated rats had atrophic ovaries and uteri consistent with blockade of endogenous estradiol activity. Short-term parenteral E3 or EE3 therapy using 10 to 30 micrograms/kg/day (35-100 microns/kg/day) rapidly differentiated virgin rat mammary glands without impairment of subsequent estrus cycles and offers an alternative to castration or life-long antiestrogen therapy for reduction of risk of radiogenic mammary carcinoma.Mammary carcinomas have been induced by 3.5 Gy whole-body gamma radiation administered at age 40 to 50 days to virgin female Sprague-Dawley rats. In 142 irradiated controls carcinoma incidence averaged 7.8% in survivors observed less than 300 days and 38.3% of those surviving longer (P less than 0.001 by t test). Mammary cancer promotion was inhibited by two methods: estriol (E3) 638 micrograms/month (2.2 microns/mo) subcutaneously for natural life span begun 2 weeks after exposure reduced cancer incidence from 76% in controls to 48% after 331 to 449 mean days observation until neoplasia was palpable (P less than 0.02 by chi-square analysis). Uterine weights were similar in control and treated groups, and were 15% to 18% greater than uteri of nonirradiated controls from other simultaneous experiments. Six monthly 638-micrograms doses of 17 alpha ethinyl estriol (EE3) reduced tumors from 88% in controls to 64% (P less than 0.05 by chi-square analysis) and delayed cancer onset (P less than 0.01-0.04 by life table analysis). Ethinyl estradiol (EE2) after 6 months' treatment similarly delayed mammary tumor development reducing incidence to 75% (NS), with a six-fold increase in nonmammary epithelial malignant tumors. Estriol administration begun between 3 days before to 5 days after radiation did not alter mammary cancer incidence in six experiments. Monthly implantation of 2.5 mg tamoxifen (4.44 microns/mo) started 2 weeks after radiation reduced mammary cancer incidence from 83% to 14% after 307 to 314 days' observation (P less than 0.001 by chi-square analysis). Treated rats had atrophic ovaries and uteri consistent with blockade of endogenous estradiol activity. Short-term parenteral E3 or EE3 therapy using 10 to 30 micrograms/kg/day (35-100 microns/kg/day) rapidly differentiated virgin rat mammary glands without impairment of subsequent estrus cycles and offers an alternative to castration or life-long antiestrogen therapy for reduction of risk of radiogenic mammary carcinoma. |
| Author | Peterson, C Rodriguez-Sierra, J F Kumar, P F Abbo, K M Lemon, H M |
| Author_xml | – sequence: 1 givenname: H M surname: Lemon fullname: Lemon, H M organization: Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68105 – sequence: 2 givenname: P F surname: Kumar fullname: Kumar, P F – sequence: 3 givenname: C surname: Peterson fullname: Peterson, C – sequence: 4 givenname: J F surname: Rodriguez-Sierra fullname: Rodriguez-Sierra, J F – sequence: 5 givenname: K M surname: Abbo fullname: Abbo, K M |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/2702580$$D View this record in MEDLINE/PubMed |
| BookMark | eNotj01LAzEYhHOo1Fr9CUJOooetb5LNJqkiSPGjUvCi4G1Js-9qZDep2S20_94VexqGGYZ5TsgoxICELBjMGAC_ZmBUBiznl8wYAAnsqhBzc8sKLedz66vMBZe45lAIMKDuxAxmLt7wbDciEwDQmczFxzE56brvwSouxZiMuQIuNUzIyzJ8-bXvfQw01jTZysdPDN7R1ratTXvqbHI-xNZSH4a87-h6T7Hrk48NjYn2to07X2M4JUe1bTo8O-iUvD8-vC2es9Xr03Jxv8qcFFJlFriq80IIXQEydExjhU6iM0YKKxQiEwXqXBa1RuQDWmWU4HVeWxA1c3xKLv53Nyn-bIcnZes7h01jA8ZtVyptuB72h-L5obhdt1iVm-T_iMoDPP8FSrNmkw |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1002/1097-0142(19900501)63:9<1685::aid-cncr2820630907>3.0.co;2-x |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 2702580 |
| Genre | Research Support, U.S. Gov't, P.H.S Comparative Study Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: NICHD NIH HHS grantid: HD 13219 |
| GroupedDBID | --- -~X .GA .GJ 05W 0R~ 1CY 1L6 1OC 24P 29B 33P 3SF 3WU 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52T 52U 52V 52W 52X 53G 5GY 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 85S 8UM 930 AAESR AAHHS AAONW AARRQ AAWTL ABCQN ABEML ABHFT ABIVO ABJNI ABLJU ABOCM ABPPZ ACGFO ACGFS ACNCT ACPRK ACSCC ACXQS ADBBV ADKYN ADOZA ADZMN ADZOD AENEX AEUQT AFBPY AFFPM AFRAH AGNAY AI. AIAGR ALAGY ALMA_UNASSIGNED_HOLDINGS AMBMR ATUGU AZBYB BAFTC BAWUL BY8 C45 CGR CS3 CUY CVF D-6 D-7 D-E D-F DIK DR2 DRFUL E3Z EBS ECM EIF EJD F04 F5P FD6 GNP GODZA GX1 H.X HBH HHY HHZ HZ~ IH2 IX1 J0M J5H JPC KQQ KZ1 L7B LATKE LC2 LC3 LITHE LOXES LSO LUTES LW6 MK4 MRFUL MRMAN MSFUL MSSTM N04 N05 N9A NEJ NF~ NNB NPM O66 O9- OHT OIG OK1 OVD P2P P2W P2X P2Z P4B Q.N QRW RWI RX1 SJN SUPJJ TEORI UDS UHB V8K V9Y VH1 VXZ W8V W99 WBKPD WH7 WIH WIJ WIK WIN WJL WVDHM WXI XV2 Y6R YQJ Z0Y ZGI ZXP ~WT 7X8 AAMMB AEFGJ AEYWJ AGXDD AIDQK AIDYY ALUQN RSU |
| ID | FETCH-LOGICAL-c5357-a027f46338d0e1ec18edec5ec9953a37ee136e8456f8ee2282d9732f4fa03f1c2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 26 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=10.1002/1097-0142(19900501)63:9<1685::aid-cncr2820630907>3.0.co;2-x&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0008-543X |
| IngestDate | Sun Nov 09 09:44:58 EST 2025 Wed Feb 19 02:34:19 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5357-a027f46338d0e1ec18edec5ec9953a37ee136e8456f8ee2282d9732f4fa03f1c2 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1097-0142%2819900501%2963%3A9%3C1685%3A%3AAID-CNCR2820630907%3E3.0.CO%3B2-X |
| PMID | 2702580 |
| PQID | 78928633 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_78928633 pubmed_primary_2702580 |
| PublicationCentury | 1900 |
| PublicationDate | 1 May 1989 |
| PublicationDateYYYYMMDD | 1989-05-01 |
| PublicationDate_xml | – month: 05 year: 1989 text: 1 May 1989 day: 01 |
| PublicationDecade | 1980 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cancer |
| PublicationTitleAlternate | Cancer |
| PublicationYear | 1989 |
| SSID | ssj0007253 |
| Score | 1.4623456 |
| Snippet | Mammary carcinomas have been induced by 3.5 Gy whole-body gamma radiation administered at age 40 to 50 days to virgin female Sprague-Dawley rats. In 142... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1685 |
| SubjectTerms | Animals Body Weight - drug effects Estriol - therapeutic use Ethinyl Estradiol - analogs & derivatives Ethinyl Estradiol - therapeutic use Female Mammary Neoplasms, Experimental - drug therapy Neoplasms, Radiation-Induced - drug therapy Organ Size - drug effects Rats Rats, Inbred Strains Tamoxifen - therapeutic use Uterus - pathology |
| Title | Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/2702580 https://www.proquest.com/docview/78928633 |
| Volume | 63 |
| WOSCitedRecordID | wos10.1002/1097-0142(19900501)63:9<1685::aid-cncr2820630907>3.0.co;2-x&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwELUKRVUvlK-K8ukDBziY2p44cZYKhCoqQOqqB5D2tvLaYzUSa7e7C2r_fcfZrHpCHLjkkCiSM55MZjJv3mPsjYlS-1mthQ--SJhBFE6ZRmCQaB2GQrnVi00047GdTNqzLXa0mYUpsMpNTOwDdci-_CM_bGyrbQ3w6eJSFM2o0lsdBDTusG2gRKYAuprJLVd4owcOSmmFqWCyw44HytHD0nalIrrSbxVFY2mkelfDqD1StTWjkeuC8MkvdOE2B0nl40d4L2k1H7S4-nsm2n-RTvb-71kesPtDJso_r13nIdvC9IjtnA699sfs-7d03s16RBfPkS9c6DJ5W-f53PUDb9wXHaKU5453ia6vlnx2zbEIgeRfPC_4ys3zVRcxPWE_T778OP4qBuUF4Q3QTjkqVmNFK7S0ZQq9shjQG_Rta8BBg6igRkvJV7SImgwVCutPrKKTEJXX--xuygmfMl5VLdI5B9pDBYBWeuWpLEXlFGU74YC93thoSp5d2hUuYf69nG6sdMD212aeXqwJOKZlhs5Y-eyftz5nu2tMWAEovmDbkV5pfMnu-T-rbrl41fsLHcdnpzcuvMaq |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibition+of+radiogenic+mammary+carcinoma+in+rats+by+estriol+or+tamoxifen&rft.jtitle=Cancer&rft.au=Lemon%2C+H+M&rft.au=Kumar%2C+P+F&rft.au=Peterson%2C+C&rft.au=Rodriguez-Sierra%2C+J+F&rft.date=1989-05-01&rft.issn=0008-543X&rft.volume=63&rft.issue=9&rft.spage=1685&rft_id=info:doi/10.1002%2F1097-0142%2819900501%2963%3A9%3C1685%3A%3Aaid-cncr2820630907%3E3.0.co%3B2-x&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |